It is already known that the Maitake (D-Fraction) mushroom is involved in stimulating the immune system and activating certain cells that attack cancer, including macrophages, T-cells, and natural killer cells. According to the U.S. National Cancer Institute, polysaccharide complexes present in Maitake mushrooms appear to have significant anticancer activity. However, the exact molecular mechanism of the Maitake antitumoral effect is still unclear. Previously, we have reported that Maitake (D-Fraction) induces apoptosis in breast cancer cells by activation of BCL2-antagonist/killer 1 (BAK1) gene expression. At the present work, we are identifying which genes are responsible for the suppression of the tumoral phenotype mechanism induced by Maitake (D-Fraction) in breast cancer cells. Human breast cancer MCF-7 cells were treated with and without increased concentrations of Maitake D-Fraction (36, 91, 183, 367 μg/mL) for 24 h. Total RNA were isolated and cDNA microarrays were hybridized containing 25,000 human genes. Employing the cDNA microarray analysis, we found that Maitake D-Fraction modified the expression of 4068 genes (2420 were upmodulated and 1648 were downmodulated) in MCF-7 breast cancer cells in a dose-dependent manner during 24 h of treatment. The present data shows that Maitake D-Fraction suppresses the breast tumoral phenotype through a putative molecular mechanism modifying the expression of certain genes (such as IGFBP-7, ITGA2, ICAM3, SOD2, CAV-1, Cul-3, NRF2, Cycline E, ST7, and SPARC) that are involved in apoptosis stimulation, inhibition of cell growth and proliferation, cell cycle arrest, blocking migration and metastasis of tumoral cells, and inducing multidrug sensitivity. Altogether, these results suggest that Maitake D-Fraction could be a potential new target for breast cancer chemoprevention and treatment.
Get full access to this article
View all access options for this article.
References
1.
MayellM. Maitake extracts and their therapeutic potential—a review. Altern Med Rev, 2001; 6:48–60.
AdachiY, OkazakiM, OhnoN, YadomaeT. Enhancement of cytokine production by macrophages stimulated with (1→3)-beta-D-glucan, grifolan (GRN), isolated from Grifola frondosa. Biol Pharm Bull, 1994; 17:1554–1560.
5.
AdachiY, OhnoN, YadomaeT. Activation of murine kupffer cells by administration with gel-forming (1–3)-beta-D-glucan from Grifola frondosa. Biol Pharm Bull, 1998; 21:278–283.
6.
OhnoN, EgawaY, HashimotoT, AdachiY, YadomaeT. Effect of beta-glucans on the nitric oxide synthesis by peritoneal macrophage in mice. Biol Pharm Bull, 1996; 19:608–612.
7.
SuzukiI, ItaniT, OhnoNet al.Effect of a polysaccharide fraction from Grifola frondosa on immune response in mice. J Pharmacobiodyn, 1985; 8:217–226.
8.
SuzukiI, HashimotoK, OikawaS, SatoK, OsawaM, YadomaeT. Antitumor and immunomodulating activities of a beta-glucan obtained from liquid-cultured Grifola frondosa. Chem Pharm Bull, 1989; 37:410–413.
9.
KuboK, NanbaH. Modification of cellular immune responses in experimental autoimmune hepatitis in mice by maitake (Grifola frondosa)Mycoscience, 1998; 39:351–360.
10.
SoaresR, MeirelesM, RochaAet al.Maitake (D Fraction) mushroom extract induces apoptosis in breast cancer cells by BAK-1 gene activation. J Med Food, 2011; 14:563–572.
11.
SambrookJ, FritschEF, ManiatisT. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: New York, 1989.
12.
GentlemanRC, CareyVJ, BatesDMet al.Bioconductor: open software development for computational biology and bioinformatics. Genome Biol, 2004; 5:R80.
13.
WettenhallJM, SmythGK. LimmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics, 2004; 20:3705–3706.
14.
SmythGK. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. GentlemanR, CareyV, DudoitS, IrizarryR, HuberW. Springer: New York, 2005; 397–420.
15.
BenjaminiY, HochbergY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B, 1995; 57:289–300.
XieJ, GuoQ. PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. J Biol Chem, 2005; 280:13824–13832.
25.
TangMJ, TaiIT. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem, 2007; 282:34457–34467.
26.
KataokaT, HollerN, MicheauOet al.BCL-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. J Biol Chem, 2001; 276:19548–19554.
27.
SajiM, RingelMD. The PI3K-AKT-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol, 2010; 321:20–28.
28.
VivancoI, SawyersCL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer, 2002; 2:489–501.
29.
SherrCJ, RobertsJM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 1999; 13:1501–1512.
30.
SaidTK, MoraesRC, SinghU, KittrellFS, MedinaD. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ, 2001; 12:285–295.
31.
StendahlM, NilssonS, WigerupCet al.p27Kip1 is a predictive factor for Tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. Int J Cancer, 2010; 127:2851–2858.
32.
ChuIM, HengstL, SlingerlandJM. p27 as Jekyll and Hyde. Regulation of cell cycle and cell motility. Cell Cycle, 2009; 8:3455–3461.
33.
PohlG, RudasM, DietzeOet al.High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol, 2003; 21:3594–3600.
34.
RBBP4. Retinoblastoma Binding Protein 4 [Homo sapiens]www.ncbi.nlm.nih.gov/gene/5928
35.
KimYG, KimMJ, LimJS, LeeMS, KimJS, YooYD. ICAM-3-induced cancer cell proliferation through the PI3K/Akt pathway. Cancer Lett, 2006; 239:103–110.
36.
CooperWN, DickinsonRE, DallolAet al.Nuclear localization and epigenetic inactivation of the RAS effector/tumour suppressor RASSF2A in multiple human cancers. Oncogene, 2008; 27:1805–1811.
37.
ElliottRL, BlobeGC. Role of transforming growth factor Beta in human cancer. J Clin Oncol, 2005; 23:2078–2093.
38.
DerynckR, MiyazonoK. TGF-β and the TGF-β family. The TGF-β Family. DernyckR, MiyazonoK. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2008; 29–44.
39.
ChenCR, KangY, SiegelPM, MassagueJ. E2F4/5 and p107 as Smad cofactors linking the TGF-beta receptor to c-myc repression. Cell, 2002; 110:19–32.
40.
SchmiererB, HillCS. Kinetic analysis of Smad nucleocytoplasmic shuttling reveals a mechanism for transforming growth factor beta-dependent nuclear accumulation of Smads. Mol Cell Biol, 2005; 25:9845–9858.
41.
LinX, DuanX, LiangYYet al.PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell, 2006; 125:915–928.
42.
DaiF, LinX, ChangC, FengXH. Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-β signaling. Dev Cell, 2009; 16:345–357.
43.
PerksCP, HollyJMP. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia, 2008; 13:455–469.
44.
SubramanianA, SharmaAK, BanerjeeD, JiangWG, MokbelK. Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer. Anticancer Res, 2007; 27:3513–3518.
45.
AmemiyaY, YangW, BenatarTet al.Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res Treat, 2011; 126:373–384.
46.
ButtAJ, DicksonKA, McDougallF, BaxterRC. Insulin-like growth factor binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem, 2003; 278:29676–29685.
47.
LeeSW, ReimerCL, OhP, CampbellDB, SchnitzerJE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene, 1998; 16:1391–1397.
48.
FiucciG, RavidD, ReichR, LiscovitchM. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene, 2002; 21:2365–2375.
49.
DolcetX, LlobetD, PallaresJ, Matias-GuiuX. NF-κB in development and progression of human cancer. Virchows Arch, 2005; 446:475–482.
50.
LinR, GewertD, HiscottJ. Differential transcriptional activation in vitro by NF-kappa B/Rel proteins. J Biol Chem, 1995; 270:3123–3131.
51.
LuoJL, KamataH, KarinM. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest, 2005; 115:2625–2632.
52.
FunkSE, SageEH. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci USA, 1991; 88:2648–2652.
53.
MotamedK, SageEH. SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J Cell Biochem, 1998; 70:543–552.
54.
TaiIT, DaiM, OwenDA, ChenLB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest, 2005; 115:1492–1502.
RichardsonAL, WangZC, De NicoloAet al.X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell, 2006; 9:121–132.
57.
Van ’t VeerLJ, DaiH, van de VijverMJet al.Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002; 415:530–536.
58.
DoughteryER, JianpingH, BittnerML. Validation of computational methods in genomics. Curr Genomics, 2007; 8:1–19.
59.
MostovichLA, PrudnikovaTY, KondratovAGet al.Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors. Cell Adh Migr, 2011; 5:395–401.
60.
AnedchenkoEA, DmitrievAA, KrasnovGSet al.Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer. Mol Biol, 2008; 42:965–976.
61.
ParrC, JiangWG. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer, 2009; 45:1673–1683.
62.
ParkJK, ParkSH, SoK, BaeIH, YooYD, UmHD. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via AKT and CREB. Int J Oncol, 2010; 36:181–192.
63.
YuQ, TooleBP, StamenkovicI. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med, 1997; 186:1985–1996.
64.
YuQ, StamenkovicI. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev, 1999; 13:35–48.
65.
Van RoyenN, VoskuilM, HoeferIet al.CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization. Circulation, 2004; 109:1647–1652.
66.
SloanEK, StanleyKL, AndersonRL. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene, 2004; 23:7893–7897.
67.
SotgiaF, Martinez-OutschoornUE, HowellA, PestellRG, PavlidesS, LisantiMP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol Mech Dis, 2012; 7:423–467.
68.
SavageK, LambrosMB, RobertsonDet al.Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res, 2007; 13:90–101.
69.
ChiuWT, LeeHT, HuangFJet al.Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res, 2011; 71:4932–4943.
70.
RobeyRW, PolgarO, DeekenJ, ToKW, BatesSE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev, 2007; 26:39–57.
71.
DoyleLA, YangW, AbruzzoLVet al.A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA, 1998; 95:15665–15670.
72.
TaiIT, DaiM, OwenDA, ChenLB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest, 2005; 115:1492–1502.
73.
RahmanM, ChanAP, TaiIT. A peptide of SPARC interferes with the interaction between caspase 8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS One, 2011; 6:e26390
74.
BasuG, Van VickleG, GhazalpourAet al.Frequency distribution of SPARC in triple-negative breast cancer patients [abstract]J Clin Oncol, 2011; 29:s27.
75.
ChungYM, KimBG, ParkCSet al.Increased expression of ICAM3 is associated with radiation resistance in cervical cancer. Int J Cancer, 2005; 117:194–201.
LoignonM, MiaoW, HuLet al.Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther, 2009; 8:2432–2440.
78.
MiaoW, LoignonM, HuL, BasikM, BatistG. Cullin-3 is a potential novel target for breast cancer chemoprevention and treatment. ASCO Annual Meeting Proceedings Part I. J Clin Oncol, 2006; 24,18Suppl:13070.
79.
HooiCF, BlancherC, QiuWet al.ST7-mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix. Oncogene, 2006; 25:3924–3933.
80.
AkkiprikM, FengY, WangHet al.Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res, 2008; 10:212–225.
81.
LiX, CaoX, LiX, ZhangW, FengY. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci, 2007; 98:1592–1596.
82.
YiuGK, ChanWY, NgSWet al.SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol, 2001; 159:609–622.
83.
BrekkenRA, PuolakkainenP, GravesDC, WorkmanG, LubkinSR, SageEH. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest, 2003; 111:487–495.
84.
PuolakkainenPA, BrekkenRA, MuneerS, SageEH. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res, 2004; 2:215–224.
85.
AbeysingheHR, CaoQ, XuJet al.THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genet Cytogenet, 2003; 143:125–132.
86.
WeydertC, RolingB, LiuJet al.Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol Cancer Ther, 2003; 2:361–369.
87.
LiC, ZhouHM. The role of manganese superoxide dismutase in inflammation defense. Enzyme Res, 2011; 2011:6.
88.
TsaiSM, HouMF, WuSHet al.Expression of manganese superoxide dismutase in patients with breast cancer. J Med Sci, 2011; 27:167–172.
89.
HeikkinenT, GrecoD, PelttariLMet al.Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res, 2011; 13:11.
90.
SaalLH, JohanssonP, HolmKet al.Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA, 2007; 104:7564–7569.
91.
Echiburú-ChauC, RoyD, CalafGM. Deleterious MnSOD signals lead to abnormal breast cell proliferation by radiation and estrogen exposure. Int J Oncol, 2011; 38:1703–1711.
92.
SotgiaF, Martinez-OutschoornUE, LisantiMP. Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?BMC Med, 2011; 9:62–66.
93.
MaherMP, WuNT, GuoHQ, DubinAE, ChaplanSR, WickendenAD. HCN channels as targets for drug discovery. Comb Chem High Throughput Screen, 2009; 12:64–72.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
